Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Japan Drug Approval Standards

Leo Pharma Files For Approval Of Psoriasis Combination Drug In Japan

This article was originally published in PharmAsia News

Executive Summary

Leo Pharma has applied for the approval of a combination agent for the treatment of psoriasis in Japan, the company announced Aug. 23.

Leo Pharma has applied for the approval of a combination agent for the treatment of psoriasis in Japan, the company announced on Aug. 23. The drug is a combination of calcipotriol – an active form of vitamin D3 –and betamethasone dipropionate ester, a corticosteroid. If approved, the agent will be the first external use combination drug for psoriasis in Japan. The drug was first launched in Denmark in 2001 and has since been approved in 97 countries including the U.S. (Click Here For More – Japanese Language)

“Leo Pharma Applies For Approval Of Psoriasis Combination Drug For External Use” - mixonline.jp 8/26/2013
Table

View full table

Topics

Tags:
BioPharmaceutical Japan Drug Approval Standards
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC085319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By